Early analgesic effects of intravenous parecoxib and rectal diclofenac following laparoscopic sterilization: A double-blind, double-dummy randomized controlled trial

Journal of Opioid Management

Volumn 4, Issue 1, 2008, Pages 49-53

  Ng, Alexander ^a,b   Swami, Ajay ^b   Smith, Graham ^b   Emembolu, Joe ^b  

^a NEW CROSS HOSPITAL   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Analgesics anti inflammatory; Cyclooxygenase 2 inhibitors; analgesics nonopioid; Diclofenac; analgesics nonopioid; Parecoxib; Randomized trial

Indexed keywords

ANTIEMETIC AGENT; COCODAMOL; CYCLIZINE; DICLOFENAC; FENTANYL; MORPHINE; NEUROMUSCULAR BLOCKING AGENT; ONDANSETRON; PARECOXIB; PROPOFOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FEMALE STERILIZATION; GENERAL ANESTHESIA; HUMAN; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; PAIN ASSESSMENT; POSTOPERATIVE CARE; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE PAIN; PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

EID: 41549108402     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2008.0008     Document Type: Article

References (20)

1. Ng A, Habib A, Swami A, et al.: Prospective randomised double-blind placebo controlled clinical trial investigating the effect of transcervical papaverine and bupivacaine on postoperative analgesic requirements following laparoscopic application of Filshie clips. Eur J Anaesthesiol. 2002; 19: 803-807.
2. Ng A, Parker J, Toogood L, et al.: Does the opioid-sparing effects of rectal diclofenac following total abdominal hysterectomy benefit the patient? Br J Anaesth. 2002; 88: 714-716.
3. Cheer SM, Goa KL: Parecoxib (parecoxib sodium). Drugs. 2001; 61: 1133-1141.
4. Ng A, Smith G, Davidson AC: Analgesic effects of parecoxib following total abdominal hysterectomy. Br J Anaesth. 2003; 90: 746-749.
5. DeLoach LJ, Higgins MS, Caplan AB, et al.: The visual analogue scale in the immediate postoperative period: Intrasubject variability and correlation with a numeric scale. Anesth Analg. 1998; 86: 102-106.
6. Romsing J, Moiniche S: A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for postoperative pain. Acta Anaesthesiol Scand. 2004; 48: 525-546.
7. Davies NM, Anderson KE: Clinical pharmacokinetics of diclofenac. Clin Pharmacokinet. 1997; 33: 184-213.
8. Ramakrishna S, Fadnavis NW, Diwan PV: Comparative pharmacokinetic evaluation of compressed suppositories of diclofenac sodium in humans. Arzneim-Forsch/Drug Res. 1996; 46: 175-177.
9. Ng A, Temple A, Smith G, et al.: Early analgesic effects of parecoxib vs ketorolac following laparoscopic sterilisation: A randomised controlled trial. Br J Anaesth. 2004; 92: 846-849.
10. Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The Class Study: A randomised controlled trial. JAMA. 2000; 284: 1247-1255.
11. Warltier DC, Marret F, Flahault A, et al.: Effects of postoperative, nonsteroidal, anti-inflammatory drugs on bleeding risk after tonsillectomy. Meta-analysis of randomized controlled trials. Anesthesiology. 2003; 98: 1497-1502.
12. Joshi W, Connelly NR, Reuben SS, et al.: An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management. Anesth Analg. 2003; 97: 35-38.
13. Juni P, Nartey L, Reichenbach S, et al.: Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet. 2004; 364: 2021-2029.
14. Bresalier RS, Sandler RS, Quan H, et al.: The adenomatous polyp prevention on Vioxx (APPROVe) cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352: 1092-1102.
15. Gottlieb S: Warnings issued over COX-2 inhibitors in US and UK. BMJ 2005; 330: 9.
16. Solomon SD, McMurray JJV, Pfeffer MA, et al.: The adenoma prevention with celecoxib (APC) study. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352: 1071-1080.
17. Nussmeier NA, Whelton AA, Brown MT, et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-1091.
18. Ott E, Nussmeier NA, Duke PC, et al.: Efficacy and safety of he cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003; 125: 1481-1492.
19. Lloyd K: Important New Safety Information Cardiovascular Risk, Celecoxib, Valdecoxib, Parecoxib. Pfizer 2005 publications.
20. Ng A, Swanevelder J: Does the opioid-sparing effect of NSAIDs benefit the patient in the postoperative period? J Opioid Manage. 2005; 1: 67-69.